Altea Therapeutics Achieves Successful Transdermal Delivery of Therapeutic Carbohydrate Macromolecules.Signs Research Agreement with Major Pharmaceutical Company ATLANTA, Ga. -- Altea Therapeutics has entered into a research agreement with an undisclosed major pharmaceutical company to examine the feasibility of developing a transdermal patch transdermal patch: see skin patch. product that delivers certain macromolecular mac·ro·mol·e·cule n. A very large molecule, such as a polymer or protein, consisting of many smaller structural units linked together. Also called supermolecule. carbohydrates for the treatment of coagulation disorders Coagulation Disorders Definition Coagulation disorders deal with disruption of the body's ability to control blood clotting. The most commonly known coagulation disorder is hemophilia, a condition in which patients bleed for long periods of time before . Altea Therapeutics also announces that it has demonstrated the transdermal delivery of carbohydrate macromolecules Macromolecules A large molecule composed of thousands of atoms. Mentioned in: Gene Therapy macromolecules in animal studies using its novel transdermal patch technology. This new research collaboration will focus on additional animal studies to assess the feasibility of the product for clinical development. The collaborative agreement gives the companies the option to enter into a broader licensing agreement for clinical development and commercialization of the product. Earlier this year, Altea Therapeutics announced research agreements with two undisclosed pharmaceutical companies to examine the feasibility of developing transdermal patch products for certain currently injected protein drugs. About Altea Therapeutics Altea Therapeutics is an emerging specialty pharmaceutical company developing and commercializing products based on a new transdermal patch technology that can deliver sustained therapeutic levels of highly water-soluble drugs, carbohydrates, nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. , peptides and proteins through the skin in a convenient, painless, and cost-effective manner. Altea Therapeutics has demonstrated in several clinical studies that its patented PassPort Transdermal System achieves what existing transdermal patches are unable to do, namely the continuous delivery through the skin of compounds that are typically administered by needle injections. The company is conducting several clinical trials in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. for its products, including for an insulin transdermal patch that provides continuous delivery of basal levels of insulin for people with diabetes, a fentanyl citrate fentanyl citrate n. A narcotic analgesic used as a supplementary analgesic agent in general anesthesia. fentanyl citrate Warning - High-alert drug! Sublimaze transdermal patch that enables rapid and safe management of moderate to severe pain, and an apomorphine hydrochloride apomorphine hydrochloride APO-go (UK), Apokyn Pharmacologic class: Dopaminergic, dopamine-receptor agonist Therapeutic class: Antiparkinsonian Pregnancy risk category C Actiontransdermal patch for the convenient management of advanced Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. . Furthermore, the company is in pre-clinical development with a number of product candidates, including a low-molecular-weight heparin patch for thromboses, a parathyroid hormone parathyroid hormone or parathormone, a hormone secreted by the parathyroid glands that regulates the metabolism of calcium and phosphate in the body. analog transdermal patch for osteoporosis, and an atypical antipsychotic transdermal patch for the management of psychoses.Altea Therapeutics is the recipient of the Frost & Sullivan 2007 Technology Innovation Award for its development of the PassPort System. Additional information about Altea Therapeutics may be found at www.alteatherapeutics.com. NOTE: Altea Therapeutics, PassPort, Medicines Made Better are either registered trademarks or trademarks of Altea Therapeutics Corporation, in the USA and/or other countries. All other brand names, product names, or trademarks belong to their respective holders. The statements in this press release regarding the products of Altea Therapeutics in development, product development plans, and projected financial results, are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the ability of Altea Therapeutics to both complete the design, development, and manufacturing process development of its products, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of its products. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion